<DOC>
	<DOCNO>NCT01067690</DOCNO>
	<brief_summary>The purpose study determine clinical response daily Indinavir oral administration association conventional chemotherapy base cycle systemic Vinblastine +/- Bleomycin patient affect advanced classical ( non HIV-associated ) Kaposi 's sarcoma</brief_summary>
	<brief_title>Treatment With Indinavir Chemotherapy Advanced Classical Kaposi 's Sarcoma</brief_title>
	<detailed_description>It recently demonstrate HIV protease inhibitor ( HIV-PI ) exert direct anti-angiogenic anti-tumor action block endothelial tumor cell invasion matrix metalloprotease ( MMP ) activity . Based data , start phase II trial treatment HIV-negative patient CKS HIV-PI Indinavir . Indinavir well tolerate induced KS regression/improvement early-stage disease , prolonged stabilization late-stage KS . Response require high plasma drug concentration indicate `` therapeutic '' drug threshold , associate decrease circulate endothelial cell ( CEC ) , basic fibroblast growth factor MMP2 plasma level . However , large , confluent tumor mass generally responsive ( Monini et al , AIDS 2009 ) . Thus , advance KS may benefit best treatment IND upon tumor debulking conventional chemotherapy .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>Documented diagnosis KS Negative HIV ELISA test Being classify stage III IV Age â‰¥18 year Having interrupt antiKS therapy since least 2 week Being informed nature study sign informed consent Inability give inform consent Presence concomitant disease , neoplasia ( exclude cutaneous tumor limit extension without diagnosis melanoma ) lifethreatening clinical condition would compromise compliance protocol Concomitant treatment ( within 2 week prior study ) systemic immunomodulatory agent ( i.e . glucocorticoid use immunosuppressive agent , interferon ) chemotherapy Pregnancy Monolateral nephropathy history nephrolithiasis last 5 year Any clinically relevant persistent alteration laboratory value observe screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>classical Kaposi 's sarcoma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>indinavir</keyword>
	<keyword>HIV protease inhibitor</keyword>
	<keyword>Advanced classical ( non HIV-associated ) Kaposi 's sarcoma</keyword>
</DOC>